Latest news with #SequencingRevolution2.3
Yahoo
2 days ago
- Business
- Yahoo
Liquid Biopsy Markets, 2029 - Exploring Screening, Diagnostic, and Therapy Selection Opportunities
Explore the evolving landscape of cancer diagnostics with our comprehensive report, analyzing screening, diagnostic, and therapy selection markets. Discover potential growth by cancer type and region, with insights into circulating tumor cells, cell-free DNA, and exosomes. Forecasts and valuations empower informed decisions. Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Markets by Cancer, Usage, Biomarker, Place, & Product with Price and Volume Outlook, Including Executive and Consultant Guides 2025-2029" has been added to offering. Explore the dynamic landscape of the Screening, Diagnostic, Therapy Selection, Minimal Residual Disease, and Screening Market through our comprehensive report, which provides a detailed analysis of price and volume outlooks across different types of cancer. Discover the transformative advancements in cancer diagnostics, particularly the innovative use of in vitro blood testing to detect cancer DNA, paving the way for widespread cancer screening tests. This cutting-edge technology is advancing rapidly, outpacing market growth, and offers a less invasive alternative to traditional surgical biopsies, poised to revolutionize disease diagnosis and monitoring. The report delves into the growth phase of the market, offering insights into its substantial impact on the healthcare industry. It includes a five-year forecast of market size expansion, with detailed projections segmented by country, cancer type, and usage categories-ranging from screening, diagnosis, therapy selection, to recurrence monitoring. Our analysis provides a granular breakdown for 15 countries and 4 regions, alongside specific insights on cancers such as Lung, Breast, Colorectal, Prostate, Cervical, and others. It also explores opportunities and challenges within screening, early detection, diagnostic, therapy monitoring, and recurrence monitoring realms, equipping stakeholders with essential knowledge for making informed investment decisions and accurate market valuations. Capitalizing on the exhaustive market intelligence contained within, this report empowers decision-makers to confidently navigate the evolving cancer diagnostics landscape, leveraging unprecedented technological advancements to enhance patient outcomes and streamline healthcare processes. Key Topics Covered: 1 Market Guides1.1 Liquid Biopsy Market - Strategic Situation Analysis1.2 Guide for Executives, Marketing, Sales, and Business Development Staff1.3 Guide for Management Consultants and Investment Advisors1.4 Impact of Artificial Intelligence on Liquid Biopsy Market2 Introduction and Market Definition2.1 What is Liquid Biopsy?2.2 The Sequencing Revolution2.3 Market Definition2.4 Methodology2.5 Perspective: Healthcare and the IVD Industry3 Market Overview3.1 Players in a Dynamic Market3.2 Using Biopsies3.3 Biopsy Sites3.4 The Situation Today - Biopsy Analysis3.5 Evidence of Cancer - Liquid Biopsy Technology3.6 Cancer Treatment Protocol Under Siege3.7 Structure of Industry Plays a Part4 Market Trends4.1 Factors Driving Growth4.1.1 Non-Invasive Game Changer4.1.2 Lower Cost4.1.3 Greater Accuracy4.1.4 Wide Range of Potential Uses4.1.5 Aging Population4.2 Factors Limiting Growth4.2.1 Lower prices4.2.2 Lack of Standards4.2.3 Protocol Resistance4.2.4 Initial Adoption Cost4.2.5 Conclusion4.3 Instrumentation and Automation4.3.1 Instruments Key to Market Share4.3.2 Bioinformatics Plays a Role4.4 Diagnostic Technology Development4.4.1 Next Generation Sequencing Fuels a Revolution4.4.2 Impact of NGS on pricing4.4.3 Pharmacogenomics Blurs Diagnosis and Treatment4.4.4 CGES Testing, A Brave New World4.4.5 Biochips/Giant magneto resistance based assay5 Liquid Biopsy Recent Developments5.1 Recent Developments - Importance and How to Use This Section5.1.1 Importance of These Developments5.1.2 How to Use This Section5.2 Liquid Biopsy Firm QCDx Closes Financing5.3 LabCorp Launches Liquid Biopsy5.4 OncoHelix, AstraZeneca to Provide Prostate Cancer Liquid Biopsy Testing5.5 Liquid Biopsy Developer Oxford Cancer Analytics Raises $11M5.6 GeneCentric Therapeutics Launches ExpressCT Liquid Biopsy Platform5.7 Syantra Closes Financing5.8 Concerns Over Grail Test Effectiveness5.9 Guardant Health Sues Tempus for Patent Infringement5.10 Delfi Dx Liquid Biopsy Technology Shows Promise5.11 Thermo Fisher Scientific, Bayer to Develop NGS-Based CDx5.12 Grail Details TBE Method for Cancer Monitoring5.13 Naveris HPV Liquid Biopsy Test Gets Medicare Coverage5.14 Personalis NeXT Personal Dx Early-Access Program5.15 Liquid Biopsy Shortens Time to Treatment5.16 Guardant Health MRD Test Garners Coverage5.17 IMBdx, AstraZeneca Expand Prostate Cancer Liquid Biopsy Partnership5.18 FoundationOne Liquid Biopsy Assay Gets FDA OK as Companion Diagnostic5.19 Epic Sciences Raises $24M for Breast Cancer Liquid Biopsy Test5.20 GenoMe Diagnostics Preparing DPCR-Based Ovarian Cancer Test5.21 Sophia Genetics to Commercialize Liquid Biopsy Test5.22 Agilent, Qiagen Nab FDA Approvals for Lung Cancer Treatment CDx5.23 Liquid Biopsy Startup Haystack Oncology Raises $56M5.24 Hedera Dx to Launch Liquid Biopsy Streamlined Platform5.25 PamGene Expanding Liquid Biopsy Assays5.26 Liquid Biopsy Firm Hedera Dx Raises €14M5.27 MDxHealth Plans One-Stop Shop for Prostate Cancer Dx5.28 Precision Oncology Dx Access Varies Widely in Europe5.29 Extracellular Vesicles Show Promise as Early-Stage Cancer Diagnostic5.30 Predicine Receives CE Mark for Blood and Urine Liquid Biopsy5.31 BillionToOne Launches First Liquid Biopsy Products5.32 Dxcover Advances Multicancer Detection Platform5.33 CorePath Laboratories, Cizzle Biotechnology Partner on Lung Cancer Blood Test5.34 Illumina Sues Guardant Health Over Patents5.35 Invitae to Expand Cancer Testing Portfolio5.36 Cancer Centre, Inivata Partner on Clinical Liquid Biopsy Studies5.37 IVBH Bio Takes Aim at With Liquid Biopsy Incubator5.38 Molecular Health, Eone-Diagnomics Ink Liquid Biopsy Partnership5.39 Delfi Diagnostics Looks To Fragmentation-Based Liquid Biopsy Tech5.40 BillionToOne Adapting Fetal Dx Tech for Liquid Biopsy5.41 EDGC to Expand Liquid Biopsy Space With Cell-Free DNA Platform5.42 Liquid Biopsy Startup BioCaptiva Raises £1M in Seed Funding5.43 Agilent Enters Liquid Biopsy Market with Resolution Biosciences Acquisition5.44 Bio-Techne to Acquire Asuragen for up to $320M5.45 Personalis Broadens Liquid Biopsy Offering5.46 Exact Sciences to Offer End-to-End Cancer Testing With Ashion Acquisition5.47 Delfi Diagnostics Plans Multi-Cancer Screening Test5.48 Menarini's CellSearch Shows Potential to Predict Breast Cancer Prognosis, Treatment Response5.49 Liquid Biopsy NGS Panels - Diverse Test Claims5.50 CMS Colon Cancer Screening Memo Bodes Well for Assays5.51 Natera Liquid Biopsy Test Coverage to Expand5.52 Freenome Closes Financing to Support Early Cancer Detection Trial5.53 C$2.6M Liquid Biopsy Initiative5.54 NeoGenomics, Inivata Partner for Lung Cancer Liquid Biopsy5.55 Liquid Biopsy Shows Promise as Screen for Cancers5.56 Inivata launches RaDaRT for the detection of residual disease and recurrence5.57 Liquid Biopsy Assay Detects 50+ Types of Cancer5.58 Liquid Biopsy Study Confirms Concordance with Tissue Biopsy6 Profiles of Key Players6.1 Admera Health, LLC6.2 Abbott Laboratories6.3 AccuraGen Inc.6.4 Acuamark Diagnostics6.5 Agilent6.6 Amoy Diagnostics Co., Ltd.6.7 Anchor Dx6.8 ANGLE plc6.9 Applied DNA Sciences6.10 ARUP Laboratories6.11 AVIVA Systems Biology6.12 Baylor Miraca Genetics Laboratories6.13 Beckman Coulter Diagnostics (Danaher)6.14 Becton, Dickinson and Company6.15 Berkley Lights6.16 BGI Genomics Co. Ltd6.17 BillionToOne6.18 Bioarray Genetics6.19 Biocartis6.20 Biocept, Inc.6.21 Biodesix Inc.6.22 BioFluidica6.23 Biolidics Ltd6.24 bioMerieux Diagnostics6.25 Bioneer Corporation6.26 Bio-Rad Laboratories, Inc6.27 Bio-Techne6.28 Bioview6.29 Burning Rock6.30 Cardiff Oncology6.31 CareDx6.32 Caris Molecular Diagnostics6.33 CellCarta6.34 CellMax Life6.35 Cepheid (Danaher)6.36 Circulogene6.37 Cizzle Biotech6.38 Clearbridge Biomedics6.39 Clinical Genomics6.40 Cytolumina Technologies Corp.6.41 Datar Cancer Genetics Limited6.42 Diagnologix LLC6.43 Dxcover6.44 Element Biosciences6.45 Enzo Biochem6.46 Epic Sciences6.47 Epigenomics AG6.48 Eurofins Scientific6.49 Exact Sciences6.50 Fluxion Biosciences (Cell Microsystems)6.51 Freenome6.52 Fyr Diagnostics6.53 GeneFirst Ltd.6.54 Genetron Holdings6.55 GILUPI Nanomedizin6.56 Guardant Health6.57 HansaBiomed6.58 Haystack Oncology (Quest Dx)6.59 iCellate6.60 ICON PLC6.61 Illumina6.62 Incell Dx6.63 Inivata6.64 INOVIQ6.65 Invitae Corporation6.66 J&J Innovative Medicine6.67 Lucence Health6.68 Lunglife AI Inc6.69 MDNA Life SCIENCES, Inc.6.70 MDx Health6.71 Menarini Silicon Biosystems6.72 Mesa Laboratories, Inc.6.73 Millipore Sigma6.74 Miltenyi Biotec6.75 miR Scientific6.76 Myriad Genetics6.77 Nanostring6.78 NantHealth, Inc.6.79 Natera6.80 NeoGenomics6.81 Novogene6.82 On-Chip Biotechnologies6.83 Oncocyte6.84 OncoDNA6.85 Oncimmune6.86 Oxford Nanopore Technologies6.87 PamGene6.88 Panagene6.89 Personalis6.90 PGDx (Labcorp)6.91 PrecisionMed6.92 Predicine6.93 Predictive Oncology6.94 Prenetics6.95 Promega6.96 Qiagen6.97 Rarecells SAS6.98 RareCyte6.99 Revvity6.100 Roche Diagnostics6.101 Saga Diagnostics6.102 Screencell6.103 Siemens Healthineers6.104 simfo GmbH6.105 Singlera Genomics Inc.6.106 Singular Genomics6.107 Standard BioTools6.108 Stilla Technologies6.109 Superfluid Dx6.110 Sysmex Inostics6.111 Tempus Labs, Inc.6.112 Thermo Fisher Scientific6.113 Todos Medical6.114 Ultima Genomics6.115 Veracyte6.116 VolitionRX6.117 Vortex Biosciences7 The Global Market for Liquid Biopsy Diagnostics7.1 Global Market Overview by Country7.2 Global Market by Cancer - Overview7.3 Global Market by Usage - Overview7.4 Global Market by Place - Overview7.5 Global Market by Marker - Overview7.6 Global Market by Product - Overview8 Global Liquid Biopsy Diagnostic Markets - By Cancer8.1 Breast8.2 Colorectal8.3 Cervical8.4 Lung8.5 Prostate9 Global Liquid Biopsy Diagnostic Markets - by Usage9.1 Screening9.3 Diagnostic9.4 Therapy9.5 Monitor10 Global Liquid Biopsy Diagnostic Markets - by Place10.1 Hospital Lab10.2 Lab Service10.3 Lab Outpatient11 Global Liquid Biopsy Diagnostic Markets - by Marker11.1 Circulating Tumor Cell11.2 Cell Free DNA11.3 Vesicle12 Global Liquid Biopsy Diagnostic Markets - by Product12.1 Kits12.2 Instruments12.3 Service13 Appendices13.1 Growth of Approved IVD Test Menu13.2 Growth of Approved Average IVD Test Fee13.3 The Most Used IVD Assays13.4 The Highest Grossing Assays13.5 Laboratory Fees Schedule For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
2 days ago
- Business
- Yahoo
Liquid Biopsy Markets, 2029 - Exploring Screening, Diagnostic, and Therapy Selection Opportunities
Explore the evolving landscape of cancer diagnostics with our comprehensive report, analyzing screening, diagnostic, and therapy selection markets. Discover potential growth by cancer type and region, with insights into circulating tumor cells, cell-free DNA, and exosomes. Forecasts and valuations empower informed decisions. Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Markets by Cancer, Usage, Biomarker, Place, & Product with Price and Volume Outlook, Including Executive and Consultant Guides 2025-2029" has been added to offering. Explore the dynamic landscape of the Screening, Diagnostic, Therapy Selection, Minimal Residual Disease, and Screening Market through our comprehensive report, which provides a detailed analysis of price and volume outlooks across different types of cancer. Discover the transformative advancements in cancer diagnostics, particularly the innovative use of in vitro blood testing to detect cancer DNA, paving the way for widespread cancer screening tests. This cutting-edge technology is advancing rapidly, outpacing market growth, and offers a less invasive alternative to traditional surgical biopsies, poised to revolutionize disease diagnosis and monitoring. The report delves into the growth phase of the market, offering insights into its substantial impact on the healthcare industry. It includes a five-year forecast of market size expansion, with detailed projections segmented by country, cancer type, and usage categories-ranging from screening, diagnosis, therapy selection, to recurrence monitoring. Our analysis provides a granular breakdown for 15 countries and 4 regions, alongside specific insights on cancers such as Lung, Breast, Colorectal, Prostate, Cervical, and others. It also explores opportunities and challenges within screening, early detection, diagnostic, therapy monitoring, and recurrence monitoring realms, equipping stakeholders with essential knowledge for making informed investment decisions and accurate market valuations. Capitalizing on the exhaustive market intelligence contained within, this report empowers decision-makers to confidently navigate the evolving cancer diagnostics landscape, leveraging unprecedented technological advancements to enhance patient outcomes and streamline healthcare processes. Key Topics Covered: 1 Market Guides1.1 Liquid Biopsy Market - Strategic Situation Analysis1.2 Guide for Executives, Marketing, Sales, and Business Development Staff1.3 Guide for Management Consultants and Investment Advisors1.4 Impact of Artificial Intelligence on Liquid Biopsy Market2 Introduction and Market Definition2.1 What is Liquid Biopsy?2.2 The Sequencing Revolution2.3 Market Definition2.4 Methodology2.5 Perspective: Healthcare and the IVD Industry3 Market Overview3.1 Players in a Dynamic Market3.2 Using Biopsies3.3 Biopsy Sites3.4 The Situation Today - Biopsy Analysis3.5 Evidence of Cancer - Liquid Biopsy Technology3.6 Cancer Treatment Protocol Under Siege3.7 Structure of Industry Plays a Part4 Market Trends4.1 Factors Driving Growth4.1.1 Non-Invasive Game Changer4.1.2 Lower Cost4.1.3 Greater Accuracy4.1.4 Wide Range of Potential Uses4.1.5 Aging Population4.2 Factors Limiting Growth4.2.1 Lower prices4.2.2 Lack of Standards4.2.3 Protocol Resistance4.2.4 Initial Adoption Cost4.2.5 Conclusion4.3 Instrumentation and Automation4.3.1 Instruments Key to Market Share4.3.2 Bioinformatics Plays a Role4.4 Diagnostic Technology Development4.4.1 Next Generation Sequencing Fuels a Revolution4.4.2 Impact of NGS on pricing4.4.3 Pharmacogenomics Blurs Diagnosis and Treatment4.4.4 CGES Testing, A Brave New World4.4.5 Biochips/Giant magneto resistance based assay5 Liquid Biopsy Recent Developments5.1 Recent Developments - Importance and How to Use This Section5.1.1 Importance of These Developments5.1.2 How to Use This Section5.2 Liquid Biopsy Firm QCDx Closes Financing5.3 LabCorp Launches Liquid Biopsy5.4 OncoHelix, AstraZeneca to Provide Prostate Cancer Liquid Biopsy Testing5.5 Liquid Biopsy Developer Oxford Cancer Analytics Raises $11M5.6 GeneCentric Therapeutics Launches ExpressCT Liquid Biopsy Platform5.7 Syantra Closes Financing5.8 Concerns Over Grail Test Effectiveness5.9 Guardant Health Sues Tempus for Patent Infringement5.10 Delfi Dx Liquid Biopsy Technology Shows Promise5.11 Thermo Fisher Scientific, Bayer to Develop NGS-Based CDx5.12 Grail Details TBE Method for Cancer Monitoring5.13 Naveris HPV Liquid Biopsy Test Gets Medicare Coverage5.14 Personalis NeXT Personal Dx Early-Access Program5.15 Liquid Biopsy Shortens Time to Treatment5.16 Guardant Health MRD Test Garners Coverage5.17 IMBdx, AstraZeneca Expand Prostate Cancer Liquid Biopsy Partnership5.18 FoundationOne Liquid Biopsy Assay Gets FDA OK as Companion Diagnostic5.19 Epic Sciences Raises $24M for Breast Cancer Liquid Biopsy Test5.20 GenoMe Diagnostics Preparing DPCR-Based Ovarian Cancer Test5.21 Sophia Genetics to Commercialize Liquid Biopsy Test5.22 Agilent, Qiagen Nab FDA Approvals for Lung Cancer Treatment CDx5.23 Liquid Biopsy Startup Haystack Oncology Raises $56M5.24 Hedera Dx to Launch Liquid Biopsy Streamlined Platform5.25 PamGene Expanding Liquid Biopsy Assays5.26 Liquid Biopsy Firm Hedera Dx Raises €14M5.27 MDxHealth Plans One-Stop Shop for Prostate Cancer Dx5.28 Precision Oncology Dx Access Varies Widely in Europe5.29 Extracellular Vesicles Show Promise as Early-Stage Cancer Diagnostic5.30 Predicine Receives CE Mark for Blood and Urine Liquid Biopsy5.31 BillionToOne Launches First Liquid Biopsy Products5.32 Dxcover Advances Multicancer Detection Platform5.33 CorePath Laboratories, Cizzle Biotechnology Partner on Lung Cancer Blood Test5.34 Illumina Sues Guardant Health Over Patents5.35 Invitae to Expand Cancer Testing Portfolio5.36 Cancer Centre, Inivata Partner on Clinical Liquid Biopsy Studies5.37 IVBH Bio Takes Aim at With Liquid Biopsy Incubator5.38 Molecular Health, Eone-Diagnomics Ink Liquid Biopsy Partnership5.39 Delfi Diagnostics Looks To Fragmentation-Based Liquid Biopsy Tech5.40 BillionToOne Adapting Fetal Dx Tech for Liquid Biopsy5.41 EDGC to Expand Liquid Biopsy Space With Cell-Free DNA Platform5.42 Liquid Biopsy Startup BioCaptiva Raises £1M in Seed Funding5.43 Agilent Enters Liquid Biopsy Market with Resolution Biosciences Acquisition5.44 Bio-Techne to Acquire Asuragen for up to $320M5.45 Personalis Broadens Liquid Biopsy Offering5.46 Exact Sciences to Offer End-to-End Cancer Testing With Ashion Acquisition5.47 Delfi Diagnostics Plans Multi-Cancer Screening Test5.48 Menarini's CellSearch Shows Potential to Predict Breast Cancer Prognosis, Treatment Response5.49 Liquid Biopsy NGS Panels - Diverse Test Claims5.50 CMS Colon Cancer Screening Memo Bodes Well for Assays5.51 Natera Liquid Biopsy Test Coverage to Expand5.52 Freenome Closes Financing to Support Early Cancer Detection Trial5.53 C$2.6M Liquid Biopsy Initiative5.54 NeoGenomics, Inivata Partner for Lung Cancer Liquid Biopsy5.55 Liquid Biopsy Shows Promise as Screen for Cancers5.56 Inivata launches RaDaRT for the detection of residual disease and recurrence5.57 Liquid Biopsy Assay Detects 50+ Types of Cancer5.58 Liquid Biopsy Study Confirms Concordance with Tissue Biopsy6 Profiles of Key Players6.1 Admera Health, LLC6.2 Abbott Laboratories6.3 AccuraGen Inc.6.4 Acuamark Diagnostics6.5 Agilent6.6 Amoy Diagnostics Co., Ltd.6.7 Anchor Dx6.8 ANGLE plc6.9 Applied DNA Sciences6.10 ARUP Laboratories6.11 AVIVA Systems Biology6.12 Baylor Miraca Genetics Laboratories6.13 Beckman Coulter Diagnostics (Danaher)6.14 Becton, Dickinson and Company6.15 Berkley Lights6.16 BGI Genomics Co. Ltd6.17 BillionToOne6.18 Bioarray Genetics6.19 Biocartis6.20 Biocept, Inc.6.21 Biodesix Inc.6.22 BioFluidica6.23 Biolidics Ltd6.24 bioMerieux Diagnostics6.25 Bioneer Corporation6.26 Bio-Rad Laboratories, Inc6.27 Bio-Techne6.28 Bioview6.29 Burning Rock6.30 Cardiff Oncology6.31 CareDx6.32 Caris Molecular Diagnostics6.33 CellCarta6.34 CellMax Life6.35 Cepheid (Danaher)6.36 Circulogene6.37 Cizzle Biotech6.38 Clearbridge Biomedics6.39 Clinical Genomics6.40 Cytolumina Technologies Corp.6.41 Datar Cancer Genetics Limited6.42 Diagnologix LLC6.43 Dxcover6.44 Element Biosciences6.45 Enzo Biochem6.46 Epic Sciences6.47 Epigenomics AG6.48 Eurofins Scientific6.49 Exact Sciences6.50 Fluxion Biosciences (Cell Microsystems)6.51 Freenome6.52 Fyr Diagnostics6.53 GeneFirst Ltd.6.54 Genetron Holdings6.55 GILUPI Nanomedizin6.56 Guardant Health6.57 HansaBiomed6.58 Haystack Oncology (Quest Dx)6.59 iCellate6.60 ICON PLC6.61 Illumina6.62 Incell Dx6.63 Inivata6.64 INOVIQ6.65 Invitae Corporation6.66 J&J Innovative Medicine6.67 Lucence Health6.68 Lunglife AI Inc6.69 MDNA Life SCIENCES, Inc.6.70 MDx Health6.71 Menarini Silicon Biosystems6.72 Mesa Laboratories, Inc.6.73 Millipore Sigma6.74 Miltenyi Biotec6.75 miR Scientific6.76 Myriad Genetics6.77 Nanostring6.78 NantHealth, Inc.6.79 Natera6.80 NeoGenomics6.81 Novogene6.82 On-Chip Biotechnologies6.83 Oncocyte6.84 OncoDNA6.85 Oncimmune6.86 Oxford Nanopore Technologies6.87 PamGene6.88 Panagene6.89 Personalis6.90 PGDx (Labcorp)6.91 PrecisionMed6.92 Predicine6.93 Predictive Oncology6.94 Prenetics6.95 Promega6.96 Qiagen6.97 Rarecells SAS6.98 RareCyte6.99 Revvity6.100 Roche Diagnostics6.101 Saga Diagnostics6.102 Screencell6.103 Siemens Healthineers6.104 simfo GmbH6.105 Singlera Genomics Inc.6.106 Singular Genomics6.107 Standard BioTools6.108 Stilla Technologies6.109 Superfluid Dx6.110 Sysmex Inostics6.111 Tempus Labs, Inc.6.112 Thermo Fisher Scientific6.113 Todos Medical6.114 Ultima Genomics6.115 Veracyte6.116 VolitionRX6.117 Vortex Biosciences7 The Global Market for Liquid Biopsy Diagnostics7.1 Global Market Overview by Country7.2 Global Market by Cancer - Overview7.3 Global Market by Usage - Overview7.4 Global Market by Place - Overview7.5 Global Market by Marker - Overview7.6 Global Market by Product - Overview8 Global Liquid Biopsy Diagnostic Markets - By Cancer8.1 Breast8.2 Colorectal8.3 Cervical8.4 Lung8.5 Prostate9 Global Liquid Biopsy Diagnostic Markets - by Usage9.1 Screening9.3 Diagnostic9.4 Therapy9.5 Monitor10 Global Liquid Biopsy Diagnostic Markets - by Place10.1 Hospital Lab10.2 Lab Service10.3 Lab Outpatient11 Global Liquid Biopsy Diagnostic Markets - by Marker11.1 Circulating Tumor Cell11.2 Cell Free DNA11.3 Vesicle12 Global Liquid Biopsy Diagnostic Markets - by Product12.1 Kits12.2 Instruments12.3 Service13 Appendices13.1 Growth of Approved IVD Test Menu13.2 Growth of Approved Average IVD Test Fee13.3 The Most Used IVD Assays13.4 The Highest Grossing Assays13.5 Laboratory Fees Schedule For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
